Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
about
Drug carriers based on highly protein-resistant materials for prolonged in vivo circulation timesiRNA-loaded poly(histidine-arginine)6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis.Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.Intracellular accumulation and immunological responses of lipid modified magnetic iron nanoparticles in mouse antigen processing cells.Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy.Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion.Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.EpCAM-targeted liposomal si-RNA delivery for treatment of epithelial cancer.Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Amphiphilic polymers formed from ring-opening polymerization: a strategy for the enhancement of gene delivery.Precise Photodynamic Therapy of Cancer via Subcellular Dynamic Tracing of Dual-loaded Upconversion Nanophotosensitizers.Traceable Nanoparticle Delivery of Small Interfering RNA and Retinoic Acid with Temporally Release Ability to Control Neural Stem Cell Differentiation for Alzheimer's Disease Therapy."Sheddable" PEG-lipid to balance the contradiction of PEGylation between long circulation and poor uptake.Development of bioactive materials for glioblastoma therapy.
P2860
Q26774341-D8BC4520-4A54-43F7-8331-67A4ECA8938CQ33596462-758175E3-EFD0-44F9-96A4-1440F15F1776Q35227495-B0BD91D7-B0B8-4596-9598-73EC4C570217Q36374503-A1019BB9-5F9B-4F54-AC2F-7BEF417C5CFAQ36510849-270B4440-D515-466D-A8BF-7F069CC7DD5BQ37046458-CD80AEFD-757E-4212-9729-7328B1D2DE1EQ37194157-885D4F69-47B3-4E73-9266-28EF998989FFQ38938407-B6DE7C05-D179-446E-ABE7-EE7DAD977938Q38968910-FA349E07-C535-4C13-A755-1C2431CB2DD8Q40336026-AA899878-F76E-46D9-912A-821BD56816BFQ42293222-47941EDD-0E3F-45A3-A701-A6E129BAAFEAQ50650492-6FB3D3C4-5CA7-459D-84BE-6EE40C61407DQ51336756-69708E84-A21D-48A0-896E-4413900DC34DQ54955140-68802E52-0940-495F-BC89-631411722A99
P2860
Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@en
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@nl
type
label
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@en
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@nl
prefLabel
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@en
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@nl
P2093
P1476
Enhanced endosomal/lysosomal e ...... or systemic delivery of siRNA.
@en
P2093
Fengying Dai
Guanghui Ma
Hongmei Liu
Qian Jiang
Qiang Cheng
Weipeng Cao
Xingjie Liang
Yuliang Zhao
P304
P356
10.1016/J.JCONREL.2013.12.007
P407
P50
P577
2013-12-21T00:00:00Z